Autres langues SCYNEXIS, Inc.

Actions

SCYX

US8112923094

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 18/08/2026			Varia. 5j.	Varia. 1 janv.
5,140 ^USD	+0,98%		-0,29%	+1,60%

10/08	SCYNEXIS, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
30/06	SCYNEXIS, Inc. lance une étude de phase 1 sur le SCY-770 pour le traitement de la polykystose rénale autosomique dominante	CI

Autres langues

10/08	Scynexis: Q2 Earnings Snapshot
10/08	SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
10/08	SCYNEXIS, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/06	SCYNEXIS, Inc. Initiates Phase 1 Study of SCY-770 for Treatment of Autosomal Dominant Polycystic Kidney Disease
30/06	Scynexis Initiates Phase 1 Study of SCY-770 to Treat Autosomal Dominant Polycystic Kidney Disease
30/06	SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
22/05	SCYNEXIS Announces One-for-Eight Reverse Stock Split
11/05	Scynexis: Q1 Earnings Snapshot
11/05	SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
11/05	SCYNEXIS, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20/04	SCYNEXIS, Inc. Announces Retirement of Director Steven C. Gilman
31/03	SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease
31/03	SCYNEXIS Announces $40.0 Million Private Placement
31/03	SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
30/03	SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding
04/03	Scynexis: Q4 Earnings Snapshot
04/03	SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
04/03	SCYNEXIS, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
26/02	SCYNEXIS, Inc. Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
26/02	SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247
13/02	CERo Therapeutics Holdings, Inc. Appoints Eric Francois to Board and Member of Audit Committee, Effective February 13, 2026
29/01	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting
28/01	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
21/01	Scynexis, Inc. Receives Fda Qualified Infectious Disease Product and Fast Track Designations for SCY-247